Login to Your Account



Patients Likely To Rotate Therapies

Cypress, Forest NDA In FMS Puts Drug In Line For 'Churn'

By Randall Osborne


Monday, January 7, 2008
When Pfizer Inc. won U.S. approval of its alpha-2 delta ligand Lyrica, people with fibromyalgia syndrome (FMS) gained their first official therapy for the painful, head-to-toe disorder, which brings a dreary lineup of added symptoms that include fatigue, muscle stiffness, cognitive dysfunction and insomnia. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription